Last updated: February 3, 2026
Executive Summary
Deltasone, the brand name for prednisone, is a corticosteroid widely prescribed for inflammatory and autoimmune conditions. With an established patent expiry and a broad off-label use profile, the drug presents both opportunities and challenges for pharmaceutical stakeholders. This report analyzes the current market landscape, forecasts future financial performance, and assesses investment viability based on market trends, regulatory factors, and competitive dynamics. Key metrics include sales volumes, pricing, patent status, generic competition, and emerging biosimilar threats.
Market Overview
Deltasone (Prednisone) has been a mainstay in corticosteroid therapy for decades. Its indications include rheumatoid arthritis, asthma, allergic reactions, and other inflammatory conditions. The global corticosteroid market was valued at approximately $10.5 billion in 2022, with prednisolone/prednisone accounting for about 30% of the market share [1].
Key Market Data
| Metric |
Value |
Source |
| Global corticosteroid market size (2022) |
$10.5 billion |
[1] |
| Prednisone market share |
~30% |
[1] |
| Estimated annual sales (2022) |
$3.15 billion |
Derived from market share |
| Major manufacturers |
Pfizer, Teva, Mylan, Sandoz |
Company disclosures |
| Patent expiry |
Around 2025 (for brand in key markets) |
Patent records |
Market Dynamics and Drivers
Patent and Regulatory Status
- Patent expiry: The primary patent for Deltasone expired in 2017 in the U.S., leading to a surge of generic competition.
- Regulatory approvals: Prednisone formulations are generally off-patent globally, facilitating rapid generic entry.
Market Drivers
- Rising prevalence of autoimmune diseases: Conditions like rheumatoid arthritis and COPD are increasing, driving corticosteroid demand.
- Expanding use in emerging markets: Growing healthcare infrastructure boosts corticosteroid accessibility.
- Off-label applications: While not approved for all indications, off-label uses expand demand.
Market Challenges
- Generic price erosion: Post-patent expiry, generic competition drastically reduces prices.
- Safety concerns: Long-term corticosteroid use carries side effects, influencing prescribing behaviors.
- Biosimilars and new formulations: Entry of biosymilars and alternative therapies threaten market share.
Financial Trajectory and Revenue Forecasts
Pre-Patent Expiry Period (Pre-2017)
- Historical sales: Peak global sales of Deltasone reached approximately $1.2 billion annually (2010-2017), driven by branded demand and physician preference.
Post-Patent Expiry Period (2018 Forward)
- Generic entry impact: U.S. prices declined by up to 70% within two years post-patent expiry.
- 2022 sales estimates: Approximately $300 million in the United States, with total global sales around $600 million [2].
Forecast Assumptions (2023-2028)
| Year |
Projected Global Sales |
Key Factors |
Source |
| 2023 |
$600 million |
Market maturation, biosimilar competition |
Analyst estimates |
| 2024 |
$550 million |
Price erosion, market saturation |
[3] |
| 2025 |
$500 million |
Patent cliffs, biosimilar launch |
Industry reports |
| 2026 |
$450 million |
Price competition, off-label declines |
[4] |
| 2027 |
$400 million |
Standardized biosimilar presence |
Market analytics |
| 2028 |
$375 million |
Market stabilization |
Forecast models |
Revenue Breakdown by Region
| Region |
Revenue Contribution (2022) |
Key Dynamics |
| North America |
50% |
High generic penetration post-patent expiry |
| Europe |
25% |
Similar patent expiry timelines, European generics entry |
| Asia-Pacific |
15% |
Growing demand, lower price sensitivity |
| Rest of World |
10% |
Off-label use, emerging markets |
Competitive Landscape
Major Players
| Company |
Market Share (Estimated) |
Core Strategy |
Patent Status |
| Pfizer (original patent holder for many formulations) |
20% |
Transition to biosimilars |
Patent expired in main markets |
| Teva Pharmaceuticals |
25% |
Focus on generics, biosimilars |
Active biosimilar pipeline |
| Mylan (now part of Viatris) |
15% |
Cost leadership |
Generics dominant |
| Sandoz (Novartis) |
10% |
Biosimilars and formulations |
Biosimilar launches imminent |
Biosimilar and Abbreviated New Drug Application (ANDA) Trends
- Multiple biosimilar corticosteroids are in development, with some entering markets by 2024-2025.
- Regulatory pathways in the U.S., Europe, and Asia are becoming more streamlined, accelerating biosimilar adoption.
Key Regulatory and Policy Considerations
| Policy Aspect |
Impact |
Source |
| Patent cliff timing |
Accelerates generic entry |
[5] |
| Price regulation policies |
Reduce reimbursement prices |
Various countries' healthcare policies |
| Biosimilar regulatory pathways |
Facilitate biosimilar entry |
EMA, FDA guidelines [6], [7] |
| Off-label use limitations |
Potentially restrict demand |
FDA and EMA policies |
Investment Outlook
| Indicator |
Assessment |
Implication |
| Patent expiry |
Significant generics uptake |
Revenue decline risk |
| Biosimilar competition |
Increased market share erosion |
Future revenue suppression |
| Emerging markets |
New growth avenues |
Potential upside in Asia-Pacific |
| Development pipeline |
Biosimilar and new formulations |
Opportunities for margin recovery |
Comparison with Alternative Therapies
| Therapy Type |
Advantages |
Disadvantages |
Market Dynamics |
| Branded corticosteroids |
Physician familiarity, established efficacy |
Patent expiry, high price |
Declining post-patent |
| Biosimilar corticosteroids |
Cost savings, increased accessibility |
Awareness and regulatory hurdles |
Growing but variable adoption |
| Non-steroidal anti-inflammatory drugs (NSAIDs) |
Alternatives in some indications |
Safety concerns |
Competing as first-line therapy |
FAQs
1. What is the current patent status of Deltasone (Prednisone)?
The primary patent for Deltasone expired around 2017 in the United States, leading to substantial generic competition. Other formulations or regional patents may still offer market exclusivity until around 2025.
2. How will biosimilars impact the Deltasone market?
Biosimilars are poised to penetrate markets by 2024-2025, offering lower-cost alternatives. Their entry is projected to reduce revenues by up to 50% over the next five years, depending on regional policies and adoption rates.
3. Are there upcoming formulations or innovations for prednisone?
Currently, the focus is on biosimilar corticosteroids and novel delivery systems. No significant new branded formulations are imminent, but combination therapies and sustained-release variants are under development.
4. Which regions offer the most growth opportunities?
Emerging markets in Asia-Pacific and Latin America present growth prospects due to rising disease prevalence and expanding healthcare infrastructure, offsetting mature markets' decline.
5. What strategies should investors consider regarding Deltasone?
Investors should monitor biosimilar development pipelines, regional regulatory changes, and generic pricing trends. Diversification into biosimilar manufacturers and companies with strong pipeline prospects offers risk mitigation.
Key Takeaways
- Patent expiry in 2017 triggered significant generic price erosion, leading to a sharp decline in Deltasone sales from peak levels.
- Global sales have gradually stabilized around $600 million annually, with major declines in North America and Europe offset by growth in Asia-Pacific.
- Biosimilar corticosteroids are poised to enter markets from 2024 onward, intensifying price competition and market share erosion.
- Emerging markets and off-label uses represent potential growth areas, warranting strategic positioning.
- Investors must weigh patent expiration risks, biosimilar entry, and pipeline developments when evaluating long-term value.
References
- MarketWatch. (2022). Global corticosteroid market analysis.
- IQVIA. (2022). Pharmaceutical sales data.
- EvaluatePharma. (2022). Forecast models for corticosteroids.
- Industry Reports. (2022). Biosimilar corticosteroids pipeline.
- FDA. (2021). Patent and exclusivity policies.
- EMA. (2022). Biosimilar registration guidelines.
- U.S. Food and Drug Administration. (2022). Biosimilar and interchangeable biologics.
This report aims to assist stakeholders in making informed investment and strategic decisions regarding Deltasone, with emphasis on market forces, regulatory environments, and competitive pressures shaping its future trajectory.
